|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Actelion Ltd., of Allschwil, Switzerland, reported the analysis of long-term follow-up data of primary pulmonary hypertension patients from Tracleer pivotal registration studies suggested that the use of the oral dual endothelin receptor antagonist is associated with improved survival. Analysis at 36 months found a survival rate of 86 percent for patients treated with Tracleer compared to a predicted survival rate of 48 percent. The difference between observed and predicted values at six, 12, 24 and 36 months were statistically significant (p
o Axcan Pharma Inc., of Mont St. Hilaire, Quebec, said it is increasing the price of its cash tender offer for all of the ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|